Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains tofirst-line antituberculous drugs.Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospectively.The Ehrlich-Ziehl-Neelsen (EZN) staining method was used for direct smear preparations, theBACTEC MGIT 460 TB system the Lowenstein-Jensen medium for culture planting and theBACTEC NAP test for the diagnosis of MTBC. Susceptibility tests were performed using theBACTEC MGIT 460 TB system with the streptomycin, isoniazid, rifampicin and ethambutol (SIRE)kit in accordance with the manufacturer's recommendations.Results: Of the total 138 tuberculosis (TB) cases, 44 (31.9%) were female and 94 (68.1%) were male.MTBC was most frequently isolated from pulmonary specimens (90.6%). Acid-resistant bacilli(ARB) positivity was detected in 88 (63.8%) samples by EZN staining for culture-positive samples.In our study, without considering single or multiple drug resistance (MDR), total resistance rates inMTBC strains were determined for, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), andstreptomycin (SM); 10.1%, 4.3%, 2.9%, and 12.3% respectively. While the susceptibility to all drugswas 82.6%, multiple drug–resistant tuberculosis (MDR-TB) was 2.9%.Conclusion: These results are important since they are the first data reported from our provinceregarding the determination of the resistance profile to anti-TB drugs. Resistance rates in our studywere very close to the 2016 data average of the Ministry of Health of Turkey. Determination of TBresistance profiles, as well as proper and regular treatment, will contribute to the control of MDRTB.